Edwards: Transcatheter Valve Leader Proves You Can Go Home Again
نویسنده
چکیده
After exploring a number of new product markets to drive growth in the decade since its spin-off from Baxter, Edwards has found its sweet spot in its own backyard: heart valves. Through an aggressive early acquisition, the company has emerged as the leader in what looks to be the next major device product market: transcatheter valves. But in building a transcatheter valve business, Edwards must maintain its surgical customers while also selling to new physician customers: interventionalist cardiologists a clinical specialty with a history of competing with surgery.
منابع مشابه
Transcatheter Aortic Valve Replacement: A Review Article
Transcatheter aortic valve replacement (TAVR) is a novel therapeutic intervention for the replacement of severely stenotic aortic valves in high-risk patients for standard surgical procedures. Since the initial PARTNER trial results, use of TAVR has been on the rise each year. New delivery methods and different valves have been developed and modified in order to promote the minimally invasive p...
متن کاملNew Drugs and Technologies Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the Edwards SAPIENTM Transcatheter Heart Valve
Transcatheter aortic valve replacement (TAVR) has been developed as a novel approach for the treatment of high-risk patients with aortic stenosis (AS). Although surgical aortic valve replacement is the standard of care for patients with symptomatic AS, it is associated with poor outcome when applied to patients with extreme operative risk. This subset of patients is usually deferred from surger...
متن کاملTranscatheter aortic valve implantation in 2015
The last decade has seen transcatheter aortic valve implantation (TAVI) emerge as the standard of care for patients with severe symptomatic aortic stenosis deemed to be either at excessiveor high-risk for surgical aortic valve replacement (SAVR). This position is supported by three important multicentre randomized trials comparing TAVI to the historical gold standard therapies: (1) The Placemen...
متن کاملValvular Heart Disease One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry The European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve
Background—Transcatheter aortic valve implantation was developed to provide a therapeutic option for patients considered to be ineligible for, and to mitigate mortality and morbidity associated with, high-risk surgical aortic valve replacement. Methods and Results—The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to assess initial post commercial clinical t...
متن کاملTranscatheter Mitral Valve Implantation in Open Heart Surgery: An Off-Label Technique
Extensive mitral annulus calcifications are considered a contraindication for valve surgery. We describe the case of a 76-year-old female with severe mitral and aortic stenosis associated with extensive calcifications of the heart. The patient underwent an open mitroaortic valve replacement using transcatheter aortic valve implantation with an Edwards SAPIEN XT valve (Edwards Lifesciences Corp....
متن کامل